# Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

> **NCT00943917** · PHASE2 · COMPLETED · sponsor: **Intarcia Therapeutics** · enrollment: 155 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **OTHER:** ITCA 650
- **DRUG:** Exenatide Injection
- **OTHER:** Ex Inj/ITCA 650

## Key facts

- **NCT ID:** NCT00943917
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-08
- **Final completion:** 2011-02
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2015-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943917, "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00943917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*